The FDA has recently granted accelerated approval to a new drug, Qalsody (tofersen), designed to treat a rare form of amyotrophic lateral sclerosis (ALS) linked to a mutation in the SOD1 gene. Dr. Weisman, head of our clinical research department, advised in favor of approval during the FDA’s advisory board.
While our practice wasn’t directly involved in the trial, we celebrate this significant advancement in the field of ALS research, offering hope to patients affected by this form of the disease.